The purpose of this program is to provide resources to help reduce the co-occurring epidemics of HIV, hepatitis, and mental health disorders through accessible, evidence-based, culturally appropriate mental and co-occurring disorder treatment that is integrated with HIV primary care and prevention services. SAMHSA expects that this program will help reduce the incidence of HIV and improve overall health outcomes for those at-risk individuals with a mental health disorder or co-occurring disorder.
SAMHSA plans to issue 18 awards of up to $485,000 per year for up to 4 years.
Applilcation Due: Monday, April 25, 2022
The purpose of this program is to provide substance misuse and HIV prevention services to racial/ethnic minority males at risk for HIV/AIDS. The program will place an emphasis on males who have sex with other males, including transgender individuals, as well as those who identify as LGBTQ+ who are not in stable housing and reside in communities with high incidence rates of HIV. Outreach will be directed to the population of focus to assist them in receiving HIV and hepatitis testing and support services. The program will use a navigation approach (Community Health Workers, Neighborhood Navigators, and/or Peer Support Specialists) to expedite services for these populations. Organizations will have the opportunity to deliver comprehensive services (psychosocial support, medical care, housing, employment, family, education, and prescription drug assistance services) that will reduce morbidity and mortality for this high-risk population. The program will provide evidence-based substance misuse and HIV and hepatitis programming in hard-to-serve communities to reduce infections and increase protective factors using SAMHSA’s Strategic Prevention Framework.
SAMHSA plans to issue 18 awards of up to $250,000 per year for up to 5 years.
Application Due: Monday, May 2, 2022
1. Community-Centered Research Collaboratives to Address Local HIV-Related Syndemics Across California.
2. Youth Mental and Sexual Health Research
Letters of Intent Due: May 19, 2022 at 12:00 PM PT
Full Applications Due: July 21, 2022 at 12:00 PM PT
For more Information, click here
Gilead Sciences, Inc. Medical Affairs Request for Novel HIV Research Applications Utilizing B/F/TAF
Gilead is now making a specific call for proposals in the disease area of HIV. This Request for Applications is in addition to the already existing Investigator Sponsored Research Program, which supports investigator-sponsored research conducted by clinicians and researchers on Gilead's marketed products or within therapeutic areas of interest to the company (https://www.gilead.com/science-and-medicine/research/investigator-sponsored-research).
Through the Medical Affairs Investigator Sponsored Research process, Gilead will evaluate and support programs which address the following two objectives:
1. Rapid ART initiation1 with B/F/TAF
2. Use of B/F/TAF, in special HIV-infected populations that traditionally have been excluded from or under recruited in the clinical trial participation
Letter of Intent (LOI: 2-page concise overview of proposed project and draft budget)
15 March 2019: LOI submission window opens
10 May 2019: LOI submission window closes
The LOI should use the format attached here and should be submitted to: email@example.com
For more information, click here